Core Viewpoint - The article highlights the advancements in Parkinson's disease treatment through the introduction of the Vercise Genus DBS system by Boston Scientific, emphasizing its potential to enhance patient outcomes and the importance of precision in treatment [2][4][5]. Group 1: Product Launch and Features - The Vercise Genus DBS system was successfully launched at the AASSFN annual meeting, providing diverse treatment options for Parkinson's disease patients in China [2]. - The system has received approval from the National Medical Products Administration and completed its first clinical applications in April 2024 [4]. - It features a unique four-channel IPG, allowing for personalized treatment solutions by covering more targets and addressing varying patient symptoms [5]. Group 2: Clinical Efficacy - A five-year multicenter clinical study indicated that the DBS system improved motor function in Parkinson's patients by 51%, with an increase of 6 hours in daily "on" time compared to pre-treatment [5]. - The quality of life for participating patients improved by 34% as a result of the treatment [5]. Group 3: Technological Innovations - The DBS therapy's effectiveness relies heavily on precise implantation and modulation of target neural nuclei, aided by the system's directional electrode design and MICC technology [6]. - The visualization control system allows doctors to see real-time changes in stimulation fields, enhancing treatment efficiency and reducing programming time by an average of 56% [6]. - The rechargeable IPG boasts an impressive lifespan of up to 25 years, significantly reducing the need for additional surgeries and providing a stable treatment experience [6].